Previous 10 | Next 10 |
2024-03-11 13:07:11 ET More on S&P 500 Index: Japan's Q4 '23 Contraction Revised Away, Helping Keep Yen Bid S&P 500: 'Everything' Is Overbought, Not Just Semis And Nvidia S&P 500: A Significant Change - Week Starting 11th March (Technical Analysis) ...
2024-03-11 12:23:20 ET More on AbCellera, Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript Biogen Alzheimer’s drug...
2024-03-07 09:59:39 ET More on Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen grant...
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most part...
New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from...
2024-03-02 04:53:00 ET On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen , (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newl...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...
2024-02-23 07:59:52 ET More on Biogen Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation DOJ issues subpoena for info on...
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the...
News, Short Squeeze, Breakout and More Instantly...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday. Biogen reported first-quarter adjusted EPS of $...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...